13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.5B | -$200M | 0.0% | -10.4% | $285M | — | $781M |
| 2024 | $2.6B | -$1.0B | 0.0% | -39.7% | $283M | — | $1.3B |
| 2023 | $2.6B | -$220M | 0.0% | -9.6% | $339M | — | $1.1B |
| 2022 | $2.4B | -$13.7B | 69.1% | -567.3% | $173M | — | $918M |
| 2021 | $2.0B | -$429M | 68.0% | -13.1% | $185M | — | $893M |
| 2020 | $1.1B | -$485M | 64.3% | -46.3% | -$58M | — | $733M |
| 2019 | — | -$99M | — | — | $26M | — | $514M |
| 2018 | — | -$97M | — | — | -$9M | — | $424M |
| 2017 | — | -$107M | — | — | -$37M | — | $43M |
| 2016 | — | -$74M | — | — | -$54M | $44M | $50M |
| 2015 | — | -$58M | — | — | -$53M | $26M | $55M |
| 2014 | — | -$17M | — | — | — | $26M | $46M |
| 2013 | — | -$6M | — | — | — | — | $3M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $614M | -$64M | 0.0% | -10.1% | $8M | — | $751M |
| Dec '25 | $642M | -$25M | 0.0% | -5.6% | $85M | — | $781M |
| Sep '25 | $626M | -$50M | 0.0% | -8.3% | $97M | — | $726M |
| Jun '25 | $632M | -$33M | 0.0% | -8.6% | $90M | — | $680M |
| Mar '25 | $629M | -$93M | 0.0% | -19.2% | $13M | — | $1.2B |
| Dec '24 | $640M | -$48M | 0.0% | -7.5% | $80M | — | $1.3B |
| Sep '24 | $641M | -$33M | 0.0% | -6.9% | $109M | — | $1.2B |
| Jun '24 | $642M | -$838M | 0.0% | -130.9% | $87M | — | $1.2B |
| Mar '24 | $646M | -$82M | 0.0% | -13.5% | $8M | — | $1.1B |
| Dec '23 | $661M | -$29M | 0.0% | -5.3% | $129M | — | $1.1B |
| Sep '23 | $660M | -$57M | 0.0% | -9.8% | $100M | — | $1.0B |
| Jun '23 | $652M | -$65M | 70.8% | -11.0% | $99M | — | $959M |
| Mar '23 | $629M | -$69M | 69.8% | -12.3% | $11M | — | $889M |
| Dec '22 | $638M | -$3.8B | 70.4% | -598.3% | $59M | — | $918M |
| Sep '22 | $611M | -$73M | 69.6% | -11.7% | $59M | — | $900M |
| Jun '22 | $592M | -$3.1B | 69.2% | -522.7% | $90M | — | $881M |
| Mar '22 | $565M | -$6.7B | 66.9% | -1179.7% | -$36M | — | $836M |
| Dec '21 | $554M | -$11M | 68.4% | -7.5% | $80M | — | $893M |
| Sep '21 | $522M | -$84M | 67.6% | -11.6% | $75M | — | $824M |
| Jun '21 | $503M | -$134M | 68.1% | -15.7% | $50M | — | $784M |
How the market has priced TDOC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Teladoc Health, Inc.'s revenue has grown 18.3% per year. These are computed facts, not advice.
As of FY2025, Teladoc Health, Inc. reported — of total debt against $781M of cash; operating income covered interest expense -13.3×.
In FY2025, gross margin was —, operating margin -10.4%, and net margin -7.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.